Cellectis Shifts Strategy to Focus on In Vivo Gene Editing
Cellectis is transforming its strategy to concentrate on in vivo gene editing, aiming to develop long-lasting treatments for chronic diseases. The company plans to advance its lead programs and restructure its operating model.
Biotechnology company Cellectis has announced a strategic transformation to focus entirely on in vivo gene editing. The company aims to develop long-lasting treatments for chronic diseases, building on promising preclinical proof-of-concept data.
The shift will allow Cellectis to advance its two lead in vivo programs: .HEAL-101, targeting the APOC3 gene for severe hypertriglyceridemia, and .HEAL-201, targeting the PCSK9 gene for severe hypercholesterolemia. The company anticipates preliminary Phase 1 clinical data for these programs in the second half of 2027 and the first half of 2028, respectively.
The strategic realignment includes continuing existing cell therapy partnerships while discontinuing development of lasme-cel and eti-cel. This refocusing is expected to extend Cellectis' cash runway into the second half of 2028.
Previously, Cellectis focused on developing allogeneic CAR T-cell therapies for cancer. The new direction in in vivo gene editing leverages the company's TALEN® technology and aims to address significant unmet needs in the treatment of chronic diseases.